VNDA
NASDAQ · Biotechnology
Vanda Pharmaceuticals Inc
$5.93
+0.03 (+0.51%)
Financial Highlights (FY 2026)
Revenue
217.89M
Net Income
-222,302,246
Gross Margin
94.0%
Profit Margin
-102.0%
Rev Growth
-5.3%
D/E Ratio
0.02
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 94.0% | 94.0% | 30.7% | 30.7% |
| Operating Margin | -69.9% | -63.0% | 14.8% | 14.7% |
| Profit Margin | -102.0% | -96.9% | 10.4% | 10.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 217.89M | 230.06M | 122.09M | 118.94M |
| Gross Profit | 204.73M | 216.17M | 37.47M | 36.50M |
| Operating Income | -152,416,431 | -144,836,646 | 18.10M | 17.45M |
| Net Income | -222,302,246 | -211,246,987 | 12.67M | 12.10M |
| Gross Margin | 94.0% | 94.0% | 30.7% | 30.7% |
| Operating Margin | -69.9% | -63.0% | 14.8% | 14.7% |
| Profit Margin | -102.0% | -96.9% | 10.4% | 10.2% |
| Rev Growth | -5.3% | -5.3% | +22.8% | +0.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.90M | 3.90M | 139.11M | 164.30M |
| Total Equity | 170.49M | 170.49M | 288.85M | 284.24M |
| D/E Ratio | 0.02 | 0.02 | 0.48 | 0.58 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -145,355,353 | -145,800,427 | 21.61M | 18.83M |
| Free Cash Flow | — | — | 20.08M | 12.24M |